Cue Biopharma Inc. (CUE)
CUE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/0001193125-26-108287-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CUE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001645460 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $27.5M |
| Net income | -$26.6M |
| Operating income | -$26.6M |
| Net margin | -96.9% |
| Operating margin | -96.7% |
| Revenue growth | +195.7% |
| Cash | $27.1M |
| Total assets | $42.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $17.4M cash; operating cash flow -$12.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 7,264,414 (2026-08-12); 76,845,904 a year earlier; 44,959,548 three years earlier. 1y figure adjusted for split (1-for-30 overall); 3y figure adjusted for split (1-for-30 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2026-04-24 | Source 2026-04-24 |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $100K, sold $2.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $7.9M | -$153.1M | -$29.0M | $17.4M | No debt tags | $37.7M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $5.7M | -$5.2M | -$10.9M | $16.4M | No debt tags | $32.7M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $21.9M | $1.6M | -$1.1M | $27.1M | No debt tags | $27.5M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $2.1M | -$7.4M | -$9.0M | $11.7M | No debt tags | $7.1M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $3.0M | -$8.5M | -$3.4M | $27.5M | No debt tags | $8.3M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $421K | -$12.3M | -$8.2M | $13.1M | $100K | $8.0M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $1.6M | -$9.5M | -$9.0M | $22.5M | $37K | $9.3M | 10-K 2026-03-16 |
| Q3 2024 2024-09-30 | $3.3M | -$8.7M | -$7.5M | $32.4M | $1.0M | $9.5M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-05-21 |
Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.9% |
| 1 month | -17.6% |
| 3 months | -48.1% |
| Year to date | +76.2% |
| 1 year | -13.3% |
| From 52-week high | -57.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OGI | Organigram Global Inc. Common Shares | $0.7240 | -12.62% | $102.2M |
| UNCY | Unicycive Therapeutics Inc. | $3.70 | +4.23% | $103.1M |
| ORGO | Organogenesis Holdings Inc. | $0.8031 | -0.86% | $104.2M |
| DERM | Journey Medical Corporation | $3.70 | -14.55% | $104.5M |
| CLLS | Cellectis S.A. | $1.04 | -11.86% | $104.5M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier